🧾 What This Document Is

This is a DEF 14A, or "Proxy Statement." It’s a formal document a company sends to its shareholders ahead of an annual meeting. Its purpose is to give shareholders the information they need to vote on important company matters. Think of it as an invitation to the company's yearly big decision-making session, with a detailed guide on what's being voted on.

👉 In this case, Inovio Pharmaceuticals is asking shareholders to vote on electing directors, ratifying their auditor, approving executive pay, and amending their stock incentive plan. The annual meeting will be virtual on May 20, 2026.

🏢 What The Company Does

In simple terms, Inovio is a biotech company focused on DNA medicines. They are developing treatments and vaccines that use DNA to instruct the body to fight diseases. Their technology involves a proprietary device called CELLECTRA® to deliver these DNA medicines.

👉 Their lead drug candidate is INO-3107, for a rare disease called recurrent respiratory papillomatosis (RRP), which causes tumors in the airway. The FDA is currently reviewing this drug for potential accelerated approval, with a decision target date of October 30, 2026.

🗳️ What You're Voting On (The Proposals)

Shareholders have four main items to vote on at the upcoming meeting:

1. Elect 8 Directors: Vote to re-elect the entire current board for another one-year term.
2. Ratify the Auditor: Approve the appointment of Ernst & Young LLP as the company's independent accounting firm for 2026.
3. Approve Executive Pay (Advisory Vote): Cast a non-binding vote on how much the top executives were paid. This is often called "Say-on-Pay."
4. Amend the Stock Incentive Plan: Approve changes to the company's plan for issuing stock options and awards to employees and directors.

👉 The Board recommends voting FOR all four proposals.

👥 Who's Running The Show (Board of Directors)

The company has an 8-member board with a mix of skills in finance, drug development, commercialization, and governance. Key highlights:

• Independence: 75% of directors are independent (6 out of 8). Only the CEO (Dr. Shea) and the scientific founder (Dr. Weiner) are considered non-independent.
• Leadership: The Chairman role is separate from the CEO. Simon X. Benito is the independent Chairman.
• Tenure: The average time these directors have served is 9 years.
• Diversity: The board includes 4 female nominees.

👉 The board committees (Audit, Compensation, Nomination & Governance) are all fully independent and meet regularly.

💼 Executive Compensation (The Pay Package)

The proxy details how much the top executives were paid in 2025. The main components are:

• Base Salary: Fixed cash pay.
• Bonus: Annual cash incentive based on goals.
• Stock Awards: The biggest part of pay for a clinical-stage biotech. It's in the form of stock options and restricted stock units (RSUs) that vest over time, aligning the executives' interests with shareholders.

👉 For example, CEO Jacqueline E. Shea's total compensation for 2025 was approximately $3.4 million, with the majority coming from long-term equity awards.

📜 The Incentive Plan Amendment

Proposal 4 asks shareholders to approve an update to the 2023 Omnibus Incentive Plan. This is the pool the company uses to grant stock options and awards.

👉 The amendment primarily seeks to increase the number of shares available for issuance by 4.5 million shares. This ensures the company can continue to attract and retain talent by offering equity compensation.

🧠 The Analogy

Inovio is like a specialized construction crew building a new type of house (DNA medicines). The directors are the architects and foremen with different expertise (governance, finance, science). The executives like the CEO are the site managers running the daily work. The proxy statement is the blueprint and meeting agenda where the property owners (shareholders) get to vote on the crew's leadership, approve the budget (auditor), and authorize the bonus and stock plan for the managers. The main building project right now is INO-3107, which is waiting for the city inspector (the FDA) to sign off on the first floor.

🧩 Final Takeaway

This proxy statement shows Inovio at a pivotal moment. Shareholders are being asked to reaffirm the leadership team and governance structure as the company awaits a crucial FDA decision on its lead drug, INO-3107, in October 2026. The key votes are about maintaining continuity (board and auditor) and ensuring the company can retain talent (incentive plan) during this critical period.